Marc F. Ferrante
Experienced in Splenomegaly

Dr. Marc F. Ferrante

Radiology
Advanced Radiology Mri Centers Lp
1259 E Main St, 
Stamford, CT 
Experienced in Splenomegaly
Advanced Radiology Mri Centers Lp
1259 E Main St, 
Stamford, CT 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Marc Ferrante is a Radiologist in Stamford, Connecticut. Dr. Ferrante is rated as an Experienced provider by MediFind in the treatment of Splenomegaly. His top areas of expertise are Colonic Malakoplakia, ALK-Positive Non-Small Cell Lung Cancer, Gas Bloat Syndrome, Endoscopy, and Colonoscopy.

His clinical research consists of co-authoring 342 peer reviewed articles and participating in 9 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Radiology
Licenses
Diagnostic Radiology in CT
Hospital Affiliations
St Vincent's Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Locations

ADVANCED RADIOLOGY MRI CENTERS LP
1259 E Main St, Stamford, CT 06902
Other Locations
ADVANCED RADIOLOGY CONSULTANTS LLC
4 Corporate Dr, Suite 182, Shelton, CT 06484
ADVANCED RADIOLOGY MRI CENTERS LP
60 Danbury Rd, Suite 101, Wilton, CT 06897
BRIDGEPORT RADIOLOGICAL ASSOCIATES LLC
267 Grant St, Bridgeport, CT 06610
ADVANCED RADIOLOGY CONSULTANTS LLC
15 Corporate Dr, Trumbull, CT 06611
ADVANCED RADIOLOGY MRI CENTERS LP
297 Boston Post Rd, Orange, CT 06477
ADVANCED RADIOLOGY MRI CENTERS LP
2876 Main St, Stratford, CT 06614
ADVANCED RADIOLOGY MRI CENTERS LP
1055 Post Rd, Fairfield, CT 06824
ADVANCED RADIOLOGY MRI CENTERS LP
30 Danbury Rd, Wilton, CT 06897
BRIDGEPORT RADIOLOGICAL ASSOCIATES LLC
2800 Main St, Bridgeport, CT 06606

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

9 Clinical Trials

A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel-Arm, Placebo-Controlled Maintenance Study of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 2)
Enrollment Status: Completed
Publish Date: October 14, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
A Phase 3, Multicenter, Open-Label Extension Study to Evaluate the Long Term Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Ulcerative Colitis LUCENT 3
Enrollment Status: Active_not_recruiting
Publish Date: October 10, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
VERDICT: In actiVE Ulcerative Colitis, a RanDomIzed Controlled Trial for Determination of the Optimal Treatment Target
Enrollment Status: Active_not_recruiting
Publish Date: September 11, 2025
Intervention Type: Biological
Study Drug: Vedolizumab
Study Phase: Phase 4
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
A Phase 3, Multicenter, Randomized, Double-Blind, Parallel, Placebo-Controlled Induction Study of Mirikizumab in Conventional-Failed and Biologic-Failed Patients With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
Enrollment Status: Completed
Publish Date: May 31, 2025
Intervention Type: Drug
Study Drug: Mirikizumab
Study Phase: Phase 3
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo- and Active- Controlled, Treat-Through Study to Evaluate the Efficacy and Safety of Mirikizumab in Patients With Moderately to Severely Active Crohn's Disease
Enrollment Status: Completed
Publish Date: December 27, 2024
Intervention Type: Drug
Study Drugs: Mirikizumab, Ustekinumab
Study Phase: Phase 3
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
A Phase-III, Randomized, Double-blind, Parallel-group, Placebo-controlled, International, Multicentre Study to Assess Efficacy and Safety of Cx601, Adult Allogeneic Expanded Adipose-derived Stem Cells (eASC) for the Treatment of Complex Perianal Fistula(s) in Patients With Crohn's Disease Over a Period of 24 Weeks and a Follow-up Period up to 52 Weeks
Enrollment Status: Completed
Publish Date: September 19, 2024
Intervention Type: Drug, Other
Study Drug: Cx601
Study Phase: Phase 3
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
ENTYVIO® Real-World Outcomes in Bio-naïve Crohn's Disease Patients in Belgium, Australia, and Switzerland: An EVOLVE Observational Expansion Study
Enrollment Status: Completed
Publish Date: October 21, 2022
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
A Multicentre Randomized, Double-blind, Placebo-controlled Phase 2 Study to Evaluate the Safety, Tolerability, Efficacy, Dose-response, Pharmacokinetics and Pharmacodynamics of Repeat Dosing of an Anti-LAG3 Cell Depleting Monoclonal Antibody (GSK2831781) in Patients With Active Ulcerative Colitis
Enrollment Status: Terminated
Publish Date: April 27, 2022
Intervention Type: Drug
Study Drug: GSK2831781
Study Phase: Phase 2
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Multicentric, Double-blind, Placebo Controlled Clinical Trial With 5-hydroxytryptophan (5-HTP) in Patients With Inflammatory Bowel Disease in Clinical and Biologic Remission: Effect on Fatigue Scores
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Drug: 5-HTP
Study Phase: Phase 2
View 8 Less Clinical Trials

341 Total Publications

Unravelling the genetic architecture of inflammatory bowel disease multiplex families with rare and common variant polygenic risk scores.
Unravelling the genetic architecture of inflammatory bowel disease multiplex families with rare and common variant polygenic risk scores.
Journal: Journal of Crohn's & colitis
Published: September 05, 2025
Similar Doctors
Distinguished in Splenomegaly
Dr. Ruth L. Badler
Radiology
Distinguished in Splenomegaly
Dr. Ruth L. Badler
Radiology

Zwanger And Pesiri Radiology Group Llp

150 Sunrise Hwy, Suite E, 
Lindenhurst, NY 
 (25.6 miles away)
631-225-7200
Languages Spoken:
English
See accepted insurances

Ruth Badler is a Radiologist in Lindenhurst, New York. Dr. Badler is rated as a Distinguished provider by MediFind in the treatment of Splenomegaly. Her top areas of expertise are Visceromegaly, Non-Alcoholic Fatty Liver Disease, Progressive Familial Intrahepatic Cholestasis Type 3, and Progressive Familial Intrahepatic Cholestasis Type 2.

Distinguished in Splenomegaly
Dr. Paul S. Lang
Radiology
Distinguished in Splenomegaly
Dr. Paul S. Lang
Radiology

Zwanger And Pesiri Radiology Group Llp

23135 Merrick Blvd, 
Laurelton, NY 
 (29.1 miles away)
631-225-7200
Languages Spoken:
English
See accepted insurances

Paul Lang is a Radiologist in Laurelton, New York. Dr. Lang is rated as a Distinguished provider by MediFind in the treatment of Splenomegaly. His top areas of expertise are Visceromegaly, Angiomyoma, Uterine Fibroids, and Non-Alcoholic Fatty Liver Disease.

Distinguished in Splenomegaly
Dr. Carolyn Ajemian
Radiology
Distinguished in Splenomegaly
Dr. Carolyn Ajemian
Radiology

Naugatuck Valley Mri LLC

1389 W Main St, 
Waterbury, CT 
 (40.9 miles away)
203-264-7999
Languages Spoken:
English
See accepted insurances

Carolyn Ajemian is a Radiologist in Waterbury, Connecticut. Dr. Ajemian is rated as a Distinguished provider by MediFind in the treatment of Splenomegaly. Her top areas of expertise are Hepatocerebral Degeneration, Cerebellar Multiple System Atrophy, Cerebellar Degeneration, and Tenosynovitis.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Ferrante's expertise for a condition
ConditionClose
    View All 47 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile